Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LCP-Tacro vs Prograf in Kidney Transplant Recipients
NCT01666951Phase 2Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Mar 2013
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Envarsus XR in kidney transplant rejection (2 arms), sponsored by Veloxis Pharmaceuticals. Primary endpoints: Area Under the Curve at 28 days, Maximum Concentration at 28 days and 3 more. Started Nov 2012; status: completed.
02
Drugs
Envarsus XR
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01666951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666951.